title: Progression of human endometrial adenocarcinoma heterotransplanted into nude mice from hormone-sensitive to hormone resistant growth.
abstract: We have used a human tumor nude mouse model involving heterotransplantation and serial passage of an estrogen receptor (ER) positive, progesterone receptor (PgR) negative human endometrial adenocarcinoma. The effects of estradiol treatment on tumor growth, ER activation and PgR induction were investigated two and four years after heterotransplantation. In Experiment I, two years after initial heterotransplantation, tumor growth and proliferative rate showed a dose-related decrease, ER was activated by estradiol treatment (measured through an increased amount of ER bound with high affinity to nuclear element(s) (ERhs) and PgR was induced. Two years later (Experiment II), the amount of ER1s (ER measured in cytosolic fraction) as well as of ERhs was lower than at the beginning of Experiment I. ER could again be activated by estradiol treatment and PgR was also induced. However, in this experiment no effect either of tumor growth or of proliferative rate was observed during the estradiol treatment. Our study therefore indicates that an estrogen non-sensitive growth can develop during serial passages in intact, non-treated female nude mice, although the capacity for ER activation and PgR induction is maintained.
authors.affiliation: Gynecologic Section, University Hospital, Lund, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Horvath
authors.forename: M
authors.initials: M
authors.lastname: Fernö
authors.forename: B
authors.initials: B
authors.lastname: Baldetorp
authors.forename: R
authors.initials: R
authors.lastname: Cameron
authors.forename: J
authors.initials: J
authors.lastname: Ranstam
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000628:therapy; D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis; D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000032:analysis; D004351:Drug Resistance / Q000502:physiology*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000494:pharmacology; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D014183:Transplantation, Heterologous; D014594:Uterine Neoplasms / Q000473:pathology* / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D045166:Estradiol Congeners; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D004958:Estradiol; C008958:polyestradiol phosphate